MMM — Medicare/Medicaid
Patient access and maintain six protected classes for bipolar disorders and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Government entities lobbied: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA)
ALC — Alcohol and Drug Abuse
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Government entities lobbied: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Justice, Dept of (DOJ); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Veterans Affairs, Dept of (VA)